未登录

C

Constance Baer

mll munich leukemia laboratory

H指数:26

被引数:3,175

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defined genetic abnormalities shape the clonal hierarchy in acute myeloid leukemia as founding events

特定的遗传异常作为始发事件塑造急性髓系白血病中的克隆等级

LEUKEMIA & LYMPHOMA

IF2.2

2026-07-031

PRE

Two ways to complex karyotype in MDS-the role of del(5q) and TP53

MDS中复杂核型形成的两种方式——del(5q)和TP53的作用

BLOOD CANCER JOURNAL

IF11.6

2025-05-190

OA

Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis

静脉和动脉血栓事件的分子预测因子在骨髓纤维化患者中

ANNALS OF HEMATOLOGY

IF2.4

2025-04-270

OA

Similarities and Differences of DNMT3A, TET2 and ASXL1 Mutations across Ccus, MDS and AML

DNMT3A、TET2和ASXL1基因突变在CCUS、MDS和AML中的相似性与差异性

IF23.1

2024-11-050

PRE

Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities- the Frequencies Vary

克隆性造血可先于具有特征性细胞遗传学异常的急性髓系白血病发生——其频率各不相同

IF23.1

2024-11-050

PRE

Phenotypic and Genetic Heterogeneity of NPM1 Mutated AML at Diagnosis and during Course of Disease

NPM1突变急性髓系白血病（AML）在诊断时及疾病过程中的表型和遗传异质性

IF23.1

2024-11-050

PRE

Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients

IF13.4

2024-05-281

OAAI

Genomic landscape of CCUS compared to MDS and its implications on risk prediction

IF13.4

2024-05-102

OAAI

The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing

IF7.1

2023-12-045

OAAI

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS

IF7.1

2023-09-1510

OAAI

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC

IF13.4

2023-08-124

OAAI

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS

IF7.1

2023-06-289

OAAI

AML classification in the year 2023: How to avoid a Babylonian confusion of languages

IF13.4

2023-04-2928

OAAI

MDS subclassification-do we still have to count blasts?

IF13.4

2023-02-2213

OAAI

Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?

IF13.4

2023-02-0119

OAAI

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts

IF13.4

2022-12-036

OAAI

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase

IF13.4

2022-10-217

OAAI

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis

IF13.4

2022-10-1919

OAAI

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics

IF13.4

2022-06-2016

OAAI

CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk

NATURE GENETICS

IF31.8

2022-05-0524

OAAI

Baer, Constance; Kimura, Shunsuke; Rana, Mitra S.; Kleist, Andrew B.; Flerlage, Tim; Feith, David J.; Chockley, Peter; Walter, Wencke; Meggendorfer, Manja; Olson, Thomas L.; Cheon, HeeJin; Olson, Kristine C.; Ratan, Aakrosh; Mueller, Martha-Lena; Foran, James M.; Janke, Laura J.; Qu, Chunxu; Porter, Shaina N.; Pruett-Miller, Shondra M.; Kalathur, Ravi C.; Haferlach, Claudia; Kern, Wolfgang; Paietta, Elisabeth; Thomas, Paul G.; Babu, M. Madan; Loughran, Thomas P.; Iacobucci, Ilaria; Haferlach, Torsten; Mullighan, Charles G.